The Use of Drug-Coated Balloons for Patients with In-Stent Restenosis
Most of the evidence supporting the efficacy and clinical value of drug-coated balloons (DCB) has been generated in patients suffering from in-stent restenosis (ISR) . Other scenarios for the use of DCB include small vessels, diffuse disease, and coronary bifurcation where the systematic implantation of a stent is not very attractive or is associated with adverse clinical and angiographic results. Information on the value of DCB in these settings is mainly based in observational registries or small clinical trials. Some studies also suggest that DCB may be of value in patients with acute myocardial infarction, a complex scenario associated with plaque rupture and a large thrombus burden where the acute results of stent implantation may not be optimal. At last DCB have been used in selected de novo lesions providing satisfactory angiographic results obtained upon dilatation.
- 6.Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis intra-stent of bare metal stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 2014;63:1378–86.CrossRefGoogle Scholar
- 8.Adriaenssens T, Dens J, Ughi G, Bennett J, et al. Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomized clinical trial. EuroIntervention. 2014;10:439–48.CrossRefGoogle Scholar
- 9.Pleva L, Kukla P, Kusnierova P, Zapletalova J, Hlinomaz O. Comparison of the efficacy of paclitaxel-eluting balloon catheters and everolimus-eluting stents in the treatment of coronary in-stent restenosis: the treatment of in-stent restenosis study. Circ Cardiovasc Interv. 2016;9:e003316.PubMedGoogle Scholar
- 17.Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.CrossRefGoogle Scholar
- 24.Agostoni P, Belkacemi A, Voskuil M, Nathoe HM, Doevendans PA, Stella PR. Serial morphological and functional assessment of drug-eluting balloon for in-stent restenotic lesions: mechanisms of action evaluated with angiography, optical coherence tomography, and fractional flow reserve. JACC Cardiovasc Interv. 2013;6(6):569–76.CrossRefGoogle Scholar
- 26.Hamm CW. Drug-coated balloons for the treatment of coronary in-stent restenosis: a randomised, multicenter, controlled clinical study. Presented at PCR 2017.Google Scholar